Med. Pro Praxi 2009; 6(3): 147-149
Combination treatment of ACE inhibitors and angiotensin receptors blockers in nephrology
- Hemodialyzační středisko, Interní hepatogastroenterologická klinika FN a LF MU, Brno
Both ACE inhibitors and angiotensin receptors blockers belong for several years to basic treatment of the chronic kidney diseases. Both
classes of drugs were shown to prevention of progression of chronic kidney disease. The effect is provided by lowering blood pressure
and concomitant blood pressure independent renoprotective effect. Based on clinical studies we can declare that ACE inhibitors and
angiotensin receptors blockers are comparable in respect to efficacy and safeness. In this regard the results of studies in cardiology
correspond to those in nephrology. There is not general agreement in the assessment of desired effect of combination of ACE inhibitors
and angiotensin receptors blockers treatment.
Keywords: ACE inhibitors, angiotensin receptors blockers, proteinuria, prevention of progression of chronic kidney disease.
Published: June 1, 2009 Show citation
References
- Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazid. Nephrol Dial Transplant 1998; 13: 1682-1685.
Go to original source... 
Go to PubMed... - Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan i patients with nepropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345: 851-860. Go to original source... Go to PubMed...
- Mogensen CE Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, mikroalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444. Go to original source... Go to PubMed...
- Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin II receptor blocker and angiotensinconverting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124. Go to original source... Go to PubMed...
- Kanno Y, Takenaka T, Nakamura T, Suzuki H. Add On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Disease and Are Treated with AngiotensinConverting Enzyme Inhibitors. CJASN 2006; 1: 730-737. Go to original source... Go to PubMed...
- Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE study. Kidney Int 2007; 72: 879-885. Go to original source... Go to PubMed...
- Rossing P, Parving HH, Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy - fact or fiction? NDT 2006; 21(9): 2354-2357. Go to original source... Go to PubMed...
- Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles Ch. Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study. J Am Soc Nephrol 2005; 777-787. Go to original source... Go to PubMed...
- Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithirahan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators. Reanl Outcomes with telmisartan, ramipril, or both, in people at high vascular risc (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372(9638): 547-553. Go to original source... Go to PubMed...
- Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446. Go to original source... Go to PubMed...